DESMOPRESSIN ACETATE

Post-LOE

desmopressin acetate

Sagent Pharmaceuticals

ANDAINJECTIONINJECTABLE

Approved

Aug 2017

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

DESMOPRESSIN ACETATE (desmopressin acetate) by Sagent Pharmaceuticals is willebrand's disease type i. Approved for nephrogenic diabetes insipidus, there is evidence of an abnormal molecular form of factor viii antigen, severe von willebrand's disease (type i) and 6 more indications. First approved in 2017.

Drug data last refreshed 21h ago

Mechanism of Action

Willebrand's disease Type I. The antidiuretic effects of desmopressin acetate are mediated by stimulation of vasopressin 2 (V2) receptors, thereby increasing water re-absorption in the kidney, and hence reducing urine production. Desmopressin acetate is a replacement hormone for antidiuretic…

Indications (7)

nephrogenic diabetes insipidus there is evidence of an abnormal molecular form of factor VIII antigen

Worked on DESMOPRESSIN ACETATE at Sagent Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

DESMOPRESSIN ACETATE

Mechanism of Action

Indications (7)

Clinical Trials (1)